Latest Articles
Endometrial Ablation | Women’s Health Wednesday - WANE 15
Endometrial Ablation | Women’s Health Wednesday WANE 15
Published: Aug. 5, 2026, 5:10 p.m.
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - EurekAlert!
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report EurekAlert!
Published: Aug. 4, 2026, 7:14 p.m.
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - eurekalert.org
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report eurekalert.org
Published: Aug. 4, 2026, 7:14 p.m.
Study finds racial differences in ultrasound evaluation of suspected endometrial cancer - Bioengineer.org
Study finds racial differences in ultrasound evaluation of suspected endometrial cancer Bioengineer.org
Published: Aug. 4, 2026, 4:58 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News
Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com
Published: Aug. 3, 2026, 3:31 p.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openPR.com
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openPR.com
Published: Aug. 3, 2026, 10:50 a.m.
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openpr.com
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openpr.com
Published: Aug. 3, 2026, 10:50 a.m.
Endometrial Cancer Market Expected to Witness Significant - openPR.com
Endometrial Cancer Market Expected to Witness Significant openPR.com
Published: Aug. 2, 2026, 5:51 p.m.
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again - londoninsider.co.uk
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again londoninsider.co.uk
Published: Aug. 1, 2026, 8:33 a.m.
Link copied to clipboard!